STOCK TITAN

Nascent Biotech Inc - NBIO STOCK NEWS

Welcome to our dedicated news page for Nascent Biotech (Ticker: NBIO), a resource for investors and traders seeking the latest updates and insights on Nascent Biotech.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nascent Biotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nascent Biotech's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.25%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.58%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
clinical trial covid-19
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.29%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.29%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.09%
Tags
none
Nascent Biotech Inc

OTC:NBIO

NBIO Rankings

NBIO Stock Data

18.64M
93.95M
40%
0.63%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
North Palm Beach

About NBIO

nascent biotech, inc. (otcmkts:nbio) is a public company, formed in march 2014, to continue development of pritumumab, a human monoclonal antibody created by a number of leading scientists who have developed various monoclonal antibodies and cytokine treatments for oncology indications. pritumumab recognizes a unique and proprietary antigen expressed on the surface of cancer cells and is being developed to treat brain and pancreatic cancers, both unmet clinical needs. nbio’s clinical premise is that the most effective way to treat disease is to modulate (boost or suppress) the human body’s natural ability to generate an immune response. often referred to as “immunotherapy”, the scientific approach is based upon two discrete types of regulatory molecules, monoclonal antibodies and cytokines that can be combined to maximize therapeutic effectiveness in a variety of diseases. monoclonal antibodies (mabs) are naturally occurring proteins that bind with exquisite specificity to molecular st